Clinical Development of Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin Lymphoma

Biomarker Research - United Kingdom
doi 10.1186/2050-7771-1-30
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phosphoinositide 3-Kinase Inhibitors in Lymphoma

Current Opinion in Oncology
Cancer ResearchOncology
2014English

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors as Cancer Therapeutics

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Non-Hodgkin Lymphoma

2020English

Phosphatidylinositol-3-Kinase Pathway

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Phosphatidylinositol 3-Kinase Inhibitors Are a Triple Threat to Ovarian Cancer

Clinical Cancer Research
Cancer ResearchOncology
2005English

Docking Study to Predict the Efficacy of Phosphatidylinositol 3-Kinase Α Inhibitors

ARO-THE SCIENTIFIC JOURNAL OF KOYA UNIVERSITY
2019English

Treating Cancer With Phosphatidylinositol-3-Kinase Inhibitors: Increasing Efficacy and Overcoming Resistance

Journal of Lipid Research
BiochemistryEndocrinologyCell Biology
2019English

Occurrence of Sarcoidosis After Chemotherapy for Non-Hodgkin Lymphoma

Korean Journal of Internal Medicine
Internal Medicine
2016English

Development of Selective Covalent Janus Kinase 3 Inhibitors

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy